RxDoctor Payments Data

Kara Hill, NP

Acute Care · Phoenix, AZNPI 1043797905

Payments from drug & device makers

$1,329in general payments, 2019–2025

Across 48 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$222
  • Hikma Pharmaceuticals USA$195
  • Nalu Medical, Inc.$136
  • Neurocrine Biosciences, Inc.$125
  • Chiesi USA, Inc.$122
  • AbbVie$122
  • plus $406 from 13 others

What the payments were for

  • Food & beverage$1,22492%
  • Education$1058%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,329 in reported general payments places this provider in the 65th percentile of 482 acute care providers in Arizona.

See all acute care providers in Arizona

Medicare billing

Part B allowed, 2024
$42,119
Medicare patients
227
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl13$10,870
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen238$7,457
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen158$6,824
MovantikNaloxegol Oxalate15$6,305
Oxycodone Hcl298$6,041
Gabapentin287$4,862
Naloxone Hcl61$3,417
Lidocaine39$2,833
Tizanidine Hcl259$2,802
Buprenorphine11$2,303
Pregabalin51$1,504
Morphine Sulfate ErMorphine Sulfate60$1,500
Duloxetine Hcl56$1,213
Baclofen74$1,097
Cyclobenzaprine Hcl94$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$222$10,87013 claims
Redhill Biopharma Inc.Movantik$20$6,30515 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl$195$3,35142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 482 acute care providers in Arizona.

Other acute care in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →